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ABSTRACT
OBJECTIVE
To assess the effects of different oral antithrombotic 
drugs that prevent saphenous vein graft failure in 
patients undergoing coronary artery bypass graft 
surgery.
DESIGN
Systematic review and network meta-analysis.
DATA SOURCES
Medline, Embase, Web of Science, CINAHL, and the 
Cochrane Library from inception to 25 January 2019.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials of participants (aged 
≥18) who received oral antithrombotic drugs 
(antiplatelets or anticoagulants) to prevent saphenous 
vein graft failure after coronary artery bypass graft 
surgery.
MAIN OUTCOME MEASURES
The primary efficacy endpoint was saphenous vein 
graft failure and the primary safety endpoint was 
major bleeding. Secondary endpoints were myocardial 
infarction and death.
RESULTS
This review identified 3266 citations, and 21 articles 
that related to 20 randomised controlled trials were 
included in the network meta-analysis. These 20 
trials comprised 4803 participants and investigated 
nine different interventions (eight active and one 
placebo). Moderate certainty evidence supports the 
use of dual antiplatelet therapy with either aspirin 
plus ticagrelor (odds ratio 0.50, 95% confidence 
interval 0.31 to 0.79, number needed to treat 10) or 
aspirin plus clopidogrel (0.60, 0.42 to 0.86, 19) to 
reduce saphenous vein graft failure when compared 
with aspirin monotherapy. The study found no strong 
evidence of differences in major bleeding, myocardial 
infarction, and death among different antithrombotic 
therapies. The possibility of intransitivity could not 
be ruled out; however, between-trial heterogeneity 
and incoherence were low in all included analyses. 
Sensitivity analysis using per graft data did not 
change the effect estimates.
CONCLUSIONS
The results of this network meta-analysis suggest an 
important absolute benefit of adding ticagrelor or 
clopidogrel to aspirin to prevent saphenous vein graft 
failure after coronary artery bypass graft surgery. Dual 
antiplatelet therapy after surgery should be tailored to 
the patient by balancing the safety and efficacy profile 
of the drug intervention against important patient 
outcomes.
STUDY REGISTRATION
PROSPERO registration number CRD42017065678.
Introduction
Coronary artery bypass graft surgery is the preferred 
treatment for many patients with multivessel coronary 
artery disease.1 2 However, patients undergoing this 
procedure remain at risk of subsequent major adverse 
cardiovascular events, mainly caused by associated 
progression of native coronary artery disease, vascular 
damage, or saphenous vein graft failure.3-7 Previous 
studies have shown rates of saphenous vein graft 
failure of up to 30-40% in the first year8 9 and up to 
70% beyond 10 years after coronary artery bypass 
graft surgery.8 10-13 Despite its relatively high early 
failure rates, saphenous vein graft remains the most 
commonly used graft in contemporary coronary artery 
bypass graft trials.14-17
Aspirin is considered the preferred antiplatelet 
drug to prevent saphenous vein graft failure after 
coronary artery bypass graft (class I, level of 
evidence A).18 Updated meta-analyses support this 
recommendation, but at a cost of increasing the 
risk of bleeding.19-21 Uncertainty remains about 
the benefits of adding a P2Y12 inhibitor or oral 
anticoagulant to aspirin monotherapy. There is 
emerging evidence on the potential benefits of dual 
antiplatelet therapy with aspirin and clopidogrel or 
ticagrelor after coronary artery bypass graft surgery, 
but these combinations have not been directly 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Aspirin is considered the preferred antiplatelet drug to prevent saphenous vein 
graft failure after coronary artery bypass surgery
Uncertainty remains about the benefits of adding a P2Y12 inhibitor or direct oral 
anticoagulant to aspirin monotherapy after bypass surgery
WHAT THIS STUDY ADDS
Dual antiplatelet therapy with either aspirin plus ticagrelor or aspirin plus 
clopidogrel was more efficacious than aspirin monotherapy in preventing 
saphenous vein graft failure after coronary artery bypass surgery
No strong evidence was found of differences in major bleeding, myocardial 
infarction, and death for different antithrombotics compared with aspirin 
monotherapy
Future guideline updates are needed to optimise antithrombotic management of 
patients undergoing coronary artery bypass graft surgery
Dual antiplatelet therapy with aspirin plus ticagrelor or aspirin plus clopidogrel 
could be considered for most patients after surgery
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compared with other antithrombotic therapies in 
randomised controlled trials. Additionally, no studies 
have been published to compare the effects of all 
available oral antithrombotic drugs (antiplatelets and 
anticoagulants) for the prevention of saphenous vein 
graft failure after coronary artery bypass graft surgery 
within a single analytical framework. Therefore, 
in this study we aimed to systematically review 
randomised controlled trials that assessed the effects 
of oral antithrombotic drugs to prevent saphenous 
vein graft failure in patients undergoing coronary 
artery bypass graft surgery. We also evaluated the 
comparative efficacy and harms of these drugs by 
using a network meta-analysis.
Methods
Literature search
This systematic review and network meta-analysis 
is reported following the Preferred Reporting Items 
for Systematic reviews and Meta-analyses (PRISMA) 
extension statement for network meta-analysis22 
(fig 1). This study is registered with PROSPERO 
(CRD42017065678) and the protocol has been peer 
reviewed and published in BMJ Open.23
We conducted a search of Medline, Embase, Web 
of Science, CINAHL, and the Cochrane Library from 
their inception to 25 January 2019. We also performed 
a grey literature search and checked reference lists of 
relevant reviews and eligible randomised controlled 
trials to ensure a comprehensive search.23 The full 
search strategy has been published in the protocol.23
Data selection
Studies were eligible for inclusion if they consisted of 
patients (≥18 years) who underwent coronary artery 
bypass graft surgery with at least one saphenous vein 
graft; if they compared oral antithrombotic regimens 
with each other or placebo; and if they evaluated 
saphenous vein graft failure, regardless of unit of 
analysis and drug regimens. Antithrombotic drugs 
included in this review were aspirin, clopidogrel, 
ticagrelor, vitamin K antagonists (warfarin, aceno-
coumarol, phenprocoumon), and rivaroxaban; dual 
antiplatelet therapy included aspirin plus clopidogrel 
or aspirin plus ticagrelor; and dual therapy included 
aspirin plus rivaroxaban. We did not include aspirin 
plus dipyridamole because this combination is no 
longer used in clinical practice for patients with 
coronary artery disease. We considered aspirin 
monotherapy as a single intervention regardless of 
whether aspirin was interrupted or continuously 
administered before coronary artery bypass graft 
surgery because a recent meta-analysis showed no 
difference between these two approaches.21
Data identification and extraction
Two investigators (KS and AAH) independently 
screened articles by title, abstract, and full text 
Full text articles excluded
Duplicate
Wrong outcome
Wrong study design
Wrong intervention
Wrong patient population
Non-extractable data
Non-English
Ongoing trials
46
13
4
26
4
4
1
7
105
Studies included in qualitative synthesis
23
Studies included in quantitative synthesis (meta-analysis), unique randomised controlled trials
Reported in 21 manuscripts
20
Full text articles assessed for eligibility
Records excluded
128
Records identified through database searching
3266
Records screened aer duplicates removed
1307
1179
Fig 1 | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram
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Table 1 | Characteristics of the included randomised controlled trials
Study, year 
(sample size)
Time of 
drug  
initiation  
after CABG
Treatment 
duration
SVG patency  
assessment method 
(unit of analysis), time 
from randomisation to 
SVG patency  
assessment Relevant study arms
No of any graft/
SVG per patient* Age (years) Male (%)
Effect size  
for SVGF, OR  
(95% CI)
Pantely, 1979 
(n=47) +3 days 6 months
Angiography  
(per patient and per  
graft), 6 months
VKA: warfarin  
(INR target: NR);  
C: no study medication
VKA: 2.85/2.85;  
C: 2.54/2.54
VKA: 56±8;  
C: 52±8
VKA: 69.2;  
C: 83.3
VKA v C: 1.04  
(0.26 to 4.18)
McEnany, 1982 
(n=216)
+3 to  
4 days 12 months
Angiography  
(per patient and per  
graft), 21.5 months  
(range 1-47 months)
VKA: warfarin  
(INR target: 1.5-2);  
ASA: 600 mg BID;  
C: matching placebo
VKA: 1.91/1.91;  
ASA: 2.03/2.03;  
C: 2.00/2.00
—
VKA: 92.9;  
ASA: 82.0;  
C: 87.3
VKA v C: 0.55  
(0.20 to 1.46); VKA v 
ASA: 0.69 (0.26 to 1.84); 
ASA v C: 0.79 (0.32 to 
1.96)
Sharma, 1983 
(n=116)
+3 to  
5 days 12 months
Angiography (per patient 
and per graft), 12 months
ASA: 325 mg TID;  
C: no study medication
ASA: 2.20/2.20;  
C: 2.20/2.20 —
ASA: 100;  
C: 100
ASA v C: 0.94  
(0.42 to 2.13)
Lorenz, 1984 
(n=60) +24 hours 4 months
Angiography (per patient 
and per graft), 4 months
ASA: 100 mg OD;  
C: matching placebo
ASA:1.90/1.90;  
C: 2.23/2.23
ASA: 55±10;  
C: 55±6
ASA: 82.8;  
C: 90.3
ASA v C: 0.23  
(0.06 to 0.79)
Brown, 1985 
(n=98)
+67± 
27 hours 12 months
Angiography (per patient 
and per graft), 12 months
ASA: 325 mg TID;  
C: matching placebo
ASA: 3.10/3.10;  
C: 3.30/3.30 — —
ASA v C: 0.52  
(0.20 to 1.32)
Goldman, 1989 
(n=98) −12 hours 12 months
Angiography (per graft),  
12 months  
(range 62-527 days)
ASA: 325 mg OD;  
C: matching placebo Overall: -/3.20
ASA: 59±8;  
C: 58±8
ASA: 100;  
C: 100
ASA v C: 0.68  
(0.39 to 1.18)
Gavaghan, 1991 
(n=237) +1 hours 12 months
Angiography (per patient 
and per graft), 12 months 
(range 222-430 days)
ASA: 324 mg OD;  
C: matching placebo
ASA: -/3.40;  
C: -/3.60
ASA:56±8;  
C: 56±7
ASA: 86.6;  
C: 83.6
ASA v C: 0.31  
(0.15 to 0.63)
Van der Meer, 
1993 (n=635)
−12 hours;  
24 hours 12 months
Angiography  
(per patient and  
per graft), 12 months
VKA: 4 mg acenocoumarol 
or 6 mg phenprocoumon 
(INR target: 2.8-4.8); ASA: 
50 mg OD
VKA: -/3.10;  
ASA: -/2.80
VKA: 58±8; 
ASA: 58±8
VKA: 88.0;  
ASA: 87.0
VKA v ASA: 0.99  
(0.67 to 1.46)
Hockings, 1993 
(n=140) −7 days 6 months
Angiography  
(per patient), 6 months
ASA: 100 mg OD;  
C: matching placebo
ASA: 3.14/2.56;  
C: 3.52/2.79
ASA: 60±9;  
C: 60±9
ASA: 94.0;  
C: 92.3
ASA v C: 0.53  
(0.16 to 1.71)
Mujanovic, 2009 
(n=20)
Immediately  
postop 3 months
Angiography (per graft),  
3 months
ASA+clopi: 100 and 75 mg 
OD, respectively; ASA:  
100 mg OD
ASA+clopi: 2.9/2.9; 
ASA: 2.7/2.7
ASA+clopi: 
58±8.5; ASA: 
60±8.5
— ASA+clopi v ASA:  0.16 (0.03 to 0.98)
Gao, 2009 
(n=197) +1 day Unclear
64-MSCTA (per graft),  
12 months
ASA+clopi: 100 and 75 mg 
OD, respectively; clopi:  
75 mg OD
ASA+clopi: 
2.66/1.71; clopi: 
2.49/1.51
ASA+clopi: 
61±10; clopi: 
62±9.9
ASA+clopi: 
82.1;  
clopi: 83.3
ASA+clopi v clopi:  
0.52 (0.17 to 1.60)
Kulik, 2010 
(n=113) 0 day 12 months
Angiography  
(per patient and  
per graft), 12 months
ASA+clopi: 162 and  
75 mg OD, respectively; 
ASA: 162 mg OD and 
matching placebo
ASA+clopi: 
3.6/2.30; ASA: 
3.4/2.24
ASA+clopi: 
65±7.5; ASA: 
68±7.4
ASA+clopi: 
91.1;  
ASA: 87.7
ASA+clopi v ASA  
1.34† (0.39 to 4.62)
Gao, 2010 
(n=249)
≤ +48  
hours 3 months
MSCTA (per graft),  
3 months
ASA+clopi: 100 and 75 mg 
OD, respectively; ASA:  
100 mg OD
ASA+clopi: 
3.18/2.14; ASA: 
3.11/2.10
ASA+clopi: 
58±8.3; ASA: 
60±7.9
ASA+clopi: 
82.3;  
ASA: 83.8
ASA+clopi v ASA:  
0.55 (0.29 to 1.04)
Sun, 2010  
(n=99)
+6 to  
48 hours 1 month
MSCTA (per patient),  
50 days
ASA+clopi: 81 and 75 mg 
OD, respectively; ASA:  
81 mg OD
ASA+clopi: 
4.03/2.35; ASA: 
3.95/2.30
ASA+clopi: 
66±9.4; ASA: 
65±9.3
ASA+clopi: 
93.9;  
ASA: 86.0
ASA+clopi v ASA:  
1.20 (0.33 to 4.32)
Mannacio, 2012 
(n=300)
+28± 
12 hours 12 months
64-MSCTA (per graft),  
12 months
ASA+clopi: 100 and 75 mg 
OD, respectively; ASA:  
100 mg OD
ASA+clopi: 
3.1/1.78; ASA: 
3.2/1.87
ASA+clopi: 
59±7.7; ASA: 
59±8.3
ASA+clopi: 
73.3;  
ASA: 75.3
ASA+clopi v ASA:  
0.55 (0.29 to 1.02)
Saw, 2016  
(n=70)
+58 to  
59 hours 3 months
128/320-MSCTA  
(per graft), 12 months
ASA+tica: 81 mg OD and  
90 mg BID, respectively; 
ASA: 81 mg OD and  
matching placebo
ASA+tica: 
2.49/1.14; ASA: 
3.43/1.69
ASA+tica: 
62±7.5; ASA: 
63±9.7
ASA+tica: 85.7;  
ASA:88.6
ASA+tica v ASA: 0.45 
(0.13 to 1.56)
Slim, 2016 
(n=20) +6 hours 8 months
128-MSCTA (per graft),  
12 months
ASA+clopi: 81 and 75 mg 
OD, respectively; ASA: 
81 mg OD and matching 
placebo
ASA+clopi: 
3.00/2.00; ASA: 
3.38/2.38
— — ASA+clopi v ASA:  0.76 (0.20 to 2.95)
Zhao, 2018 
(n=500)
+0 to  
24 hours 12 months
MSCTA (per graft),  
12 months
ASA+tica: 100 mg OD and 
90 mg BID, respectively; 
tica: 90 BID; ASA: 100 OD
ASA+tica: 
3.76/2.90; tica: 
3.83/2.94;  
ASA: 3.76/2.92
ASA+tica: 
64±8.2; tica: 
63±8.3; ASA: 
64±8.1
ASA+tica: 79.8;  
tica: 80.7;  
ASA: 84.9
ASA+tica v tica: 0.70  
(0.44 to 1.09); ASA+tica 
v ASA: 0.47 (0.27 to 
0.80); tica v ASA: 0.68 
(0.46 to 1.01)
Xu, 2018  
(n=140) NR 1 month
MSCTA (per graft),  
1 month
ASA+tica: 100 mg OD and 
90 mg BID, respectively; 
ASA+clopi: 100 mg OD and 
75 mg OD, respectively
ASA+tica: -/2.51;  
ASA+clopi: -/2.59
ASA+tica: 
59±8.9; 
ASA+clopi: 
60±7.5
ASA+tica: 77.1;  
ASA+clopi: 72.9
ASA+tica v ASA+clopi: 
0.81 (0.24 to 2.73)
Lamy, 2018 
(n=1448)
+4 to  
14 days NR
MSCTA (per graft),  
12 months
ASA+riva: 100 mg OD and 
2.5 mg BID, respectively; 
riva: 5 mg BID;  
ASA: 100 mg OD
ASA+riva: -/2.00;  
riva: -/2.00;  
ASA: -/2.00
ASA+riva: 
66±7.8; riva: 
65±7.9; ASA: 
66±8.5
ASA+riva: 78.3;  
riva: 81.2;  
ASA: 82.3
ASA+riva: v riva: 1.24  
(0.87 to 1.78); ASA+riva 
v ASA: 1.13 (0.80 to 
1.62); riva v ASA: 0.91 
(0.63 to 1.33)
Values are presented as mean±standard deviation or No (%) unless stated otherwise. ASA=aspirin; BID=twice a day; C=control; CABG=coronary artery bypass graft; clopi=clopidogrel; 
INR=international normalised ratio; MSCT=multislice computed tomography angiography; NR=not reported; OAC=oral anticoagulation; OD=once a day; OR=odds ratio; riva= rivarox-
aban; SVG=saphenous vein graft; SVGF=saphenous vein graft failure; tica=ticagrelor; TID=three times a day; VKA=vitamin K antagonist.
*Data that were not reported in the original studies were calculated from total number of grafts/number of patients enrolled.
†Calculated from Hage24 reporting long term data.
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according to prespecified inclusion criteria. The 
full text reports of potentially relevant studies were 
retrieved, and data on study and patient characteristics, 
treatment strategies, and results of all included studies 
were then independently extracted (KS and AAH/
TC) using a data extraction form. Any discrepancies 
were resolved by consensus after consulting a third 
investigator (RB).
Outcome measures
The primary efficacy outcome was the incidence of 
saphenous vein graft failure, defined as participants 
with at least one occluded saphenous vein graft as 
assessed by either invasive angiogram or computed 
tomography (table 1 and supplementary table 1). 
We prespecified a sequence in the protocol23 in case 
the overall preferred definition of total occlusion 
was not used. Because not all the included studies 
expressed saphenous vein graft failure on a per 
patient basis, we also included studies that reported 
per graft data in our base case analysis to increase 
the totality of evidence. We made the decision about 
combining per patient and per graft data after we 
compared the results from per patient14-16 25-37 and per 
graft14-17 24-36 38-40 (accounting for clustering effects) 
meta-analyses. The results for magnitude and direc-
tion of effect estimates were consistent and there 
were large overlapping 95% confidence intervals of 
effect sizes in most comparisons. Because a sensitivity 
analysis showed the per graft network meta-analysis 
and the base case network meta-analysis did not differ 
substantially, the inference for our base case analysis 
was made on per patient basis. This approach is 
clinically preferable given that treatments are applied 
to patients (and not grafts).
We calculated and used effective sample size instead 
of originally reported outcome data to account for 
clustering effects for per graft data.41-43 The effective 
sample size was estimated by using a design effect 
that includes an intra cluster correlation coefficient.43 
We obtained the intra cluster correlation coefficient 
needed to calculate the effective sample size from 
an external source.42 The size of the intra cluster 
correlation coefficient and the number of observations 
sampled within each cluster influence the power 
of the study.43 We used an intra cluster correlation 
coefficient of 0.177 for this review.42 Additionally, if 
studies reported the incidence of saphenous vein graft 
failure at multiple time points, we included the longest 
available follow-up period in our base case analysis.
The primary safety outcome was the incidence of 
major bleeding. Secondary outcomes were all cause 
mortality and myocardial infarction. These outcomes 
were binary and defined according to the definitions 
of the study authors (table 1 and supplementary table 
1). We collected data on major adverse cardiac and 
cerebrovascular events, heart failure, minor bleeding, 
red blood cell transfusion, and admission to hospital 
owing to a cardiovascular cause; however, because 
these data were sparse, we did not report them in our 
study.
Risk of bias and certainty assessment
We assessed the risk of bias in included studies by 
using the Cochrane Collaboration tool for randomised 
trials 2.044 for each outcome. We graded the certainty 
of direct and network evidence by using the Grade of 
Recommendations Assessment, Development, and 
Evaluation (GRADE) for network meta-analysis.45
Statistical analyses
We performed a frequentist network meta-analysis 
of aggregate data to obtain network estimates for 
the aforementioned outcomes of interest. The model 
framework used random effects to allow for apparent 
heterogeneity among studies in treatment comparison 
effects. We conducted a pairwise meta-analysis to 
generate direct estimates for outcomes by using a 
random effects model. Transitivity assumption, the 
distribution of patient and study characteristics that 
modify treatment effects (effect modifiers) across 
treatment comparisons, was explored to assess 
whether these characteristics were sufficiently similar 
between comparisons. Additionally, we evaluated 
incoherence assumption (the statistical disagreement 
between direct and indirect evidence in a closed loop) 
locally using a loop specific approach, and globally 
using a design by treatment interaction model.46 We 
used surface under the cumulative ranking (SUCRA)47 
to rank the intervention’s hierarchy in the network 
meta-analysis and then we estimated mean ranks. We 
used the comparison adjusted funnel plot to explore 
the potential for publication bias.47
We performed sensitivity analyses to assess the 
robustness of the model for the primary outcomes. 
We visually compared the results of the base case 
analysis with those of the per graft and in-trial data 
(to exclude the legacy effect of drug interventions) 
analyses, and excluding trials with off pump coronary 
artery bypass graft only. We performed an “all missing 
failure” analysis to explore the impact of missing data; 
this analysis assumed that all missing patients had a 
negative event.48 All outcomes of interest were binary 
and the relative treatment effects were reported as odds 
ratios with 95% confidence intervals. All analyses were 
done in Stata version 14 using the network command.
Patient and public involvement
There was no patient or public involvement around 
the research question or conception and design of the 
study. Because of the nature of the study, there was no 
patient or public involvement in any recruitment or 
conduction of the study. There was no patient or public 
involvement in measuring the outcomes, in providing 
interpretations of the findings, or writing of the results.
Results
Data selection
Our systematic search identified 3266 citations 
published between 1979 and 2019. Of these, we 
included 21 articles14-17 24-40 that related to 20 
unique parallel group randomised controlled trials 
in the network meta-analysis. These trials comprised 
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4803 participants and investigated nine different 
interventions (eight active and one placebo) (fig 1); 
three trials had three eligible arms and the remaining 
trials had two eligible arms.16 17 26
The study sample size ranged from 20 to 1448 
patients, patient age ranged from 44 to 83 years, 
83% were male, and 83% underwent elective (stable 
coronary artery disease) surgery. The number of 
saphenous vein grafts ranged from 1.14 to 3.60 per 
patient, and drug interventions were started from 
seven days before coronary artery bypass graft surgery 
to 14 days after the procedure. The duration of follow-
up ranged from one month to eight years. Assessment 
of saphenous vein graft failure was performed by 
either invasive angiography or computed tomography 
(table 114-17 24-40 and supplementary table 1).
Across comparisons, the distribution of baseline 
characteristics by treatment was generally balanced, 
except for the type of coronary artery bypass graft 
technique (on pump versus off pump coronary artery 
bypass graft), and the timing of drug initiation (table 
2). Information on antifibrinolytic use was not reported 
because of limited data.
Mixed treatment meta-analyses
Primary efficacy outcome
The network of treatment comparisons for saphenous 
vein graft failure included nine individual nodes (fig 
2, top panel). Each of the nodes represents placebo or 
different drug interventions; aspirin was the most well 
connected intervention with all other interventions 
directly linked to it, except for clopidogrel monotherapy. 
Figure 3 (top panel) shows network estimates of 
treatment effect on saphenous vein graft failure 
for different interventions compared with aspirin 
monotherapy. Network meta-analysis showed that dual 
antiplatelet therapy with either aspirin plus ticagrelor 
(odds ratio 0.50, 95% confidence interval 0.31 to 0.79, 
number needed to treat 10) or aspirin plus clopidogrel 
(0.60, 0.42 to 0.86, 19) was more efficacious than 
aspirin monotherapy to prevent saphenous vein graft 
failure. Pooled effect sizes also suggested that all active 
interventions reduced saphenous vein graft failure 
compared with placebo. However, the evidence does 
not support the efficacy of clopidogrel monotherapy in 
reducing saphenous vein graft failure compared with 
placebo (fig 3, top panel). According to SUCRA values, 
the top two ranked interventions for the reduction of 
saphenous vein graft failure were dual antiplatelet 
therapy with aspirin plus ticagrelor (94.4) and aspirin 
plus clopidogrel (85.3; table 3).
In our sensitivity analyses we used per graft data, 
excluded off pump only trials,35 36 and accounted 
for missing outcome data. The study effect estimates 
(supplementary table 2) and SUCRA values 
(supplementary table 3) did not substantially 
change. One of the included studies in our network 
meta-analysis reported post-trial24 (used in the base 
case analysis) and in-trial37 data. We performed a 
sensitivity analysis to explore the legacy effect of drug 
interventions by using in-trial data. Effect estimates 
and SUCRA values did not substantially change 
compared with the base case analysis (supplementary 
tables 2 and 3, respectively).
Primary safety outcome
Eleven randomised controlled trials15-17 24 26 31 33 34 35 39 40 
comprising 3745 patients reported the incidence 
Table 2 | Summary of baseline and procedural characteristics of patients across different treatment comparisons
Characteristics  
(No of RCTs*)
Treatment comparison (No of RCTs)
ASA v  
placebo  
(n=7)
VKA v  
control 
(n=2)
VKA v ASA  
(n=2)
Tica v ASA  
(n=1)
Riva v  
ASA  
(n=1)
ASA+riva  
v aspirin 
(n=1)
ASA+riva  
v riva  
(n=1)
ASA+clopi  
v ASA  
(n=6)
ASA+clopi  
v clopi  
(n=1)
ASA+tica  
v ASA  
(n=2)
ASA+clopi  
v ASA+tica  
(n=1)
ASA+tica v  
tica (n=1)
Age (n=17) 58±7.7 53±8 58±8 64±8.2 65±8.2 66±8.1 66±7.8 61±8.16 62±9.94 63±8.24 60±8.2 64±8.3
Male  
(n=16)
1212/1278  
(95)
129/148 
(87)
632/722  
(88)
275/332  
(83)
773/946  
(82)
774/965  
(80)
785/985  
(80)
599/736  
(81)
163/197  
(83)
336/404  
(83)
105/140  
(75)
183/217  
(84)
Diabetes  
(n=14)
45/560  
(8)
18/111 
(16)
74/722  
(10)
142/332  
(43)
412/946  
(44)
413/965  
(43)
393/985  
(40)
168/756  
(22)
108/197  
(55)
163/404  
(40)
94/140  
(67)
124/217  
(57)
Hypertension  
(n=15)
528/1218  
(43)
20/111 
(18)
250/722  
(35)
242/332  
(73) NR NR NR
417/756  
(55)
125/197  
(64)
301/404  
(75)
92/140  
(66)
176/217  
(81)
Dyslipidaemia  
(n=9)
27/116  
(23) NR
271/616  
(44)
243/332  
(73) NR NR NR
426/736  
(58)
41/197  
(21)
299/404  
(74) NR
245/292  
(84)
Prior MI  
(n=13)
703/1076  
(65)
74/111 
(67)
401/722  
(56)
103/332  
(31)
351/946  
(37)
350/965  
(36)
355/985  
(36)
253/623  
(41)
105/197  
(53)
108/404  
(27)
53/140  
(38)
102/217  
(47)
Prior PCI  
(n=5) NR NR NR NR NR NR NR
77/524  
(15)
24/197  
(12)
8/70  
(11)
18/140  
(13) NR
Prior CVA  
(n=3) NR NR NR
35/332  
(11)
29/946  
(3.1)
36/965  
(4.0)
37/985  
(3.8)
16/436  
(3.7) NR
48/334  
(14) NR
75/217  
(35)
OPCABG  
(n=16)
862/862  
(100)
37/37 
(100)
616/616  
(100)
82/332  
(25)
235/946  
(25)
228/965  
(24)
245/985  
(25)
321/776  
(41)
124/197  
(63)
85/334  
(25)
26/140  
(19)
88/217  
(41)
Elective surgery  
(n=16)
932/1006  
(93)
73/145 
(50)
695/755  
(92)
332/332  
(100)
582/946  
(61)
599/965  
(62)
601/985  
(61)
776/776  
(100)
186/197  
(94)
381/404  
(94)
140/140  
(100)
217/217  
(100)
Time of drug 
initiation  
(range) (n=20)
14 preop  
to 5 postop 
days
3-4  
postop 
days
12 preop 
hours to 4 
postop days
Within 24 
postop 
hours
4-14  
postop 
days
4-14  
postop 
days
4-14  
postop 
days
Immediately 
postop to 48 
hours
1 day
Within 24-
59 postop 
hours
NR
Within 24 
postop  
hours
Values presented as mean±standard deviation or No (%) unless stated otherwise. ASA=aspirin; clopi=clopidogrel; CVA=cerebrovascular accident; MI=myocardial infarction; NR=not reported; 
OPCABG=off pump coronary artery bypass graft; PCI=percutaneous coronary intervention; RCT=randomised controlled trial; riva=rivaroxaban; tica=ticagrelor; VKA=vitamin K antagonist.
*Number of RCTs reporting data.
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of major bleeding. The network diagram of eligible 
treatment comparisons included eight individual nodes 
(fig 2, bottom panel). Each of the nodes represents 
different active interventions or placebo, in which aspirin 
monotherapy was the most well connected intervention 
with all other interventions directly linked to it. Figure 
3 (bottom panel) shows network estimates of treatment 
effect on major bleeding for different interventions 
compared with aspirin monotherapy. Network meta-
analyses showed no evi dence of differences among all 
possible treatment comparisons. Pooled effect sizes 
also suggested that all active interventions increased 
bleeding compared with placebo, although without 
substantial statistical evidence (fig 3, bottom panel). 
Accor ding to SUCRA values, after placebo (84.4), the 
top ranked intervention associated with fewer major 
bleeding events was dual antiplatelet therapy with 
aspirin plus clopidogrel (66.5; table 3).
Sensitivity analyses that excluded one off pump 
only trial,35 accounted for missing outcome data, and 
used in-trial data did not show substantial changes 
in study effect estimates (supplementary table 4) and 
SUCRA values (supplementary table 5). When we used 
in-trial data for analysis, aspirin monotherapy and its 
combination with rivaroxaban obtained a higher rank 
(supplementary table 5).
Aspirin and ticagrelor
Aspirin and ticagrelor
Saphenous vein gra failure
Major bleeding
Aspirin and rivaroxaban
Aspirin and
rivaroxaban
Placebo
Placebo
Aspirin and
clopidogrel
Aspirin and
clopidogrel
Aspirin
Aspirin
Rivaroxaban
Rivaroxaban
Ticagrelor
Ticagrelor
Clopidogrel
Vit K A
Vit K A
1 trial
1 trial
1 trial
1 trial
1 trial
1 trial
6 trials
4 trials
1 trial
2 trials
2 trials
2 trials
2 trials
2 trials
2 trials
1 trial
1 trial1 trial
1 trial
1 trial
1 trial
7 trials
1 trial
Fig 2 | Network of treatment comparisons for saphenous vein graft failure (primary efficacy outcome) and major 
bleeding (primary safety outcome). Each node represents different active interventions or placebo. Size of nodes 
is proportional to number of studies comparing respective nodes. Increasing thickness of lines between nodes 
is proportional to number of randomly assigned patients contributing to direct comparisons. Vit K A=vitamin K 
antagonist
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Secondary outcomes
Ten randomised controlled trials14 15 25 26 29 30 31 33 37 39 
comprising 1921 patients reported all cause mortality, 
and 12 randomised controlled trials14-17 24 26 31 33 34 35 39 40 
comprising 3994 patients reported myocardial infarction. 
Figure 4 shows networks of treatment comparisons for 
secondary outcomes. Figure 5 summarises results 
for secondary outcomes. Network meta-analyses 
showed no evidence of differences among all possible 
comparisons for secondary outcomes (all cause 
mortality and myocardial infarction). Supplementary 
table 6 presents SUCRA values. The included 
randomised controlled trials sparsely reported 
other pre specified secondary outcomes; therefore, 
network meta-analyses were not conducted for these 
outcomes.
Risk of bias and certainty of evidence
We judged two randomised controlled trials27 39 to 
have a high risk of bias arising from the randomisation 
process and five randomised controlled trials24-26 30 40 
to have a high risk of bias because of missing outcome 
data (supplementary table 7). Five of the trials26 29 36 38 39 
had some concerns about measurement of the outcome 
and three randomised controlled trials27 36 38 had 
some concerns about bias from selective reporting of 
outcomes. We judged only five unique trials15 16 35 37 40 
to have a low risk of bias due to deviation from 
intended interventions. Overall, we judged eight trials 
(40%)24-28 30 39 40 to have a high risk of bias, primarily 
owing to failure to blind and missing outcome data. 
Of trials reporting incomplete outcome data, 10 
trials14-17 27 33-35 37 39 performed intention to treat 
Saphenous vein gra failure
Placebo
0.64 
(0.19 to 2.16)
0.56 
(0.42 to 0.76)
0.56 
(0.37 to 0.86)
0.45 
(0.26 to 0.79)
0.48 
(0.30 to 0.77)
0.28 
(0.16 to 0.48)
0.60 
(0.38 to 0.98)
0.34 
(0.21 to 0.54)
Clopidogrel
0.88
(0.27 to 2.84)
0.88 
(0.26 to 2.98)
0.70 
(0.20 to 2.47)
0.75
(0.22 to 2.55)
0.44
(0.13 to 1.52)
0.93
(0.27 to 3.16)
0.52 
(0.17 to 1.60)
Aspirin
1.00 
(0.71 to 1.41)
0.80 
(0.49 to 1.29)
0.85
(0.59 to 1.23)
0.50 
(0.31 to 0.79)
1.06
(0.75 to 1.50)
0.60 
(0.42 to 0.86)
Vitamin K
antagonists
0.80 
(0.44 to 1.44)
0.85
(0.51 to 1.41)
0.50 
(0.28 to 0.88)
1.06
(0.65 to 1.73)
0.60 
(0.36 to 0.98)
Ticagrelor
1.07
(0.58 to 1.95)
0.62 
(0.37 to 1.05)
1.33
(0.73 to 2.40)
0.75 
(0.42 to 1.35)
Rivaroxaban
0.58
(0.32 to 1.05)
1.25
(0.87 to 1.78)
0.70
(0.42 to 1.18)
Aspirin +
Ticagrelor
2.13 
(1.20 to 3.85)
1.20 
(0.69 to 2.09)
Aspirin +
Rivaroxaban
0.56
(0.34 to 0.93)
Aspirin + 
Clopidogrel
Major bleeding
Placebo
2.98 
(0.31 to 28.2)
5.31 
(0.56 to 50.2)
4.86 
(0.20 to 119)
4.45 
(0.42 to 47.0)
2.96 
(0.28 to 31.8)
5.74 
(0.31 to 106)
2.53 
(0.21 to 30.0)
1.78 
(0.95 to 3.34)
1.63 
(0.17 to 15.9)
1.50 
(0.73 to 3.04)
0.99 
(0.46 to 2.14)
1.93 
(0.30 to 12.4)
0.85 
(0.30 to 2.37)
Aspirin
0.91 
(0.09 to 9.69)
0.84 
(0.32 to 2.16)
0.56 
(0.21 to 1.50)
1.08 
(0.15 to 7.69)
0.48 
(0.14 to 1.59)
Vitamin K
antagonists
0.92 
(0.08 to 9.93)
0.61 
(0.06 to 6.71)
1.18 
(0.24 to 5.91)
0.52 
(0.05 to 5.39)
Ticagrelor
0.66 
(0.33 to 1.33)
1.29 
(0.18 to 9.42)
0.57 
(0.16 to 1.98)
Rivaroxaban
1.94 
(0.26 to 14.5)
0.86 
(0.24 to 3.08)
Aspirin +
Rivaroxaban
0.44 
(0.07 to 2.97)
Aspirin +
Ticagrelor
Aspirin + 
Clopidogrel
Fig 3 | Network meta-analysis and certainty of evidence for saphenous vein graft failure (primary efficacy outcome) and major bleeding (primary 
safety outcome). Results are odds ratios (95% confidence intervals) from the network meta-analysis between the column defining intervention 
and row defining intervention. Significant results are in bold. Certainty of evidence is also given: green=moderate certainty evidence, yellow=low 
certainty evidence, red=very low certainty evidence
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analysis, and two of these16 27 clearly reported the 
use of intention to treat analysis with worst case 
assumptions for imputation of missing data. It was 
unclear how the remaining trials with incomplete data 
handled missing outcome data.
Figure 3 (top panel) also provides the certainty of 
evidence of network estimates for saphenous vein 
graft failure. We downgraded evidence certainty to 
low or very low for most comparisons, mainly because 
of study limitations owing to incomplete outcome 
data, imprecision, indirectness, and the possibility 
of intransitivity. Supplementary tables 8 and 9 
summarise certainty of evidence for direct, indirect, 
and network estimates. The network evidence for dual 
antiplatelet therapy with aspirin plus ticagrelor and 
aspirin plus clopidogrel was of moderate certainty 
compared with aspirin monotherapy. The symmetrical 
comparison adjusted funnel plot shows neither 
evidence of publication bias for placebo controlled 
trials nor small study effects (supplementary figure 
1). When we performed a sensitivity analysis that 
excluded studies considered at serious risk of bias, 
the effect estimates did not change substantially, 
except for aspirin plus clopidogrel versus vitamin 
K antagonist, which became non-significant 
(supplementary figure 2).
Table 3 | Summary of network meta-analysis estimates of effects, confidence intervals, and certainty of evidence for the comparison of different 
antithrombotic drugs in patients undergoing coronary artery bypass graft surgery
Comparator (reference):  
ASA monotherapy
Relative effect, 
odds ratio (95% 
CI)*
Anticipated absolute effect, per 1000 patients† 
(95% CI)
Certainty of evidence*
NNT/NNH  
(95% CI) SUCRA‡
ASA  
monotherapy
Other  
strategies Difference 
SVGF§ (total studies: 20 RCTs; total participants: 4803):
ASA+tica  
(2 RCTs; 420 participants)
0.50 (0.31 to 0.79), 
network estimate 230 130
100 fewer  
(145 to 39 fewer)
⊕⊕⊕○, moderate,  
due to indirectness
NNT: 10  
(7 to 26) 94.4
ASA+clopi  
(6 RCTs; 1118 participants)
0.60 (0.42 to 0.86), 
network estimate 150 96
54 fewer  
(81 to 18 fewer)
⊕⊕⊕○, moderate,  
due to indirectness
NNT: 19  
(13 to 55) 85.3
ASA+riva  
(1 RCT; 1401 participants)
1.06 (0.75 to 1.50), 
network estimate 99 104
5 more  
(23 fewer to 43 more)
⊕⊕○○, low, due to  
indirectness and imprecision
Not calculated  
(non-statistically  
significant)
32.9
Tica monotherapy  
(1 RCT; 332 participants)
0.80 (0.49 to 1.29), 
network estimate 283 240
43 fewer  
(121 fewer to 54 more)
⊕⊕○○, low, due to  
indirectness and imprecision
Not calculated  
(non-statistically  
significant)
61.3
Riva monotherapy  
(1 RCT; 1351 participants)
0.85 (0.59 to 1.23), 
network estimate 99 85
14 fewer  
(38 fewer to 20 more)
⊕⊕○○, low, due to  
indirectness and imprecision
Not calculated  
(non-statistically  
significant)
58.3
VKA  
(2 RCTs; 601 participants)
1.00 (0.71 to 1.41), 
network estimate 284 284
0 fewer  
(64 fewer to 75 more)
⊕○○○, very low, due to  
risk of bias, indirectness,  
and imprecision
Not calculated  
(non-statistically  
significant)
39.7
Clopi monotherapy (no direct  
evidence, indirect evidence only) 1.14 (0.35 to 3.69) 100¶ 112
12 more  
(63 fewer to 191 more)
⊕○○○, very low, due to  
intransitivity, indirectness,  
and imprecision
Not calculated  
(non-statistically  
significant)
36.2
Placebo  
(7 RCTs; 831 participants)
1.77 (1.31 to 2.39), 
network estimate 255 377
122 more  
(55 to 195 more)
⊕⊕⊕○, moderate, due to  
indirectness NNH: 9 (6 to 19) 3.3
Major bleeding (total studies: 11 RCTs; total participants: 3745):
Placebo  
(2 RCTs; 385 participants)
0.34 (0.04 to 3.23), 
network estimate 8 3
5 fewer  
(7 fewer to 16 more)
⊕⊕○○, low, due to  
indirectness and imprecision
Not calculated  
(non-statistically  
significant)
84.4
ASA+clopi  
(5 RCTs; 518 participants)
0.85 (0.30 to 2.37), 
network estimate 33 28
5 fewer  
(23 fewer to 42 more)
⊕⊕○○, low, due to  
indirectness and imprecision
Not calculated  
(non-statistically  
significant)
66.5
ASA+riva  
(1 RCT; 965 participants)
0.99 (0.46 to 2.14), 
network estimate 28 28
0 fewer  
(15 fewer to 30 more)
⊕⊕⊕○, moderate, due to  
imprecision
Not calculated  
(non-statistically  
significant)
61.1
Riva  
(1 RCT; 946 participants)
1.50 (0.73 to 3.04), 
network estimate 28 41
13 more  
(7 fewer to 53 more)
⊕⊕⊕○, moderate,  
due to imprecision
Not calculated  
(non-statistically  
significant)
33.6
Tica  
(1 RCT; 332 participants)
1.63 (0.17 to 15.9), 
network estimate 3 5
2 more  
(2 fewer to 43 more)
⊕⊕⊕○, moderate,  
due to imprecision
Not calculated  
(non-statistically  
significant)
38.6
ASA+tica  
(2 RCTs; 404 participants)
1.93 (0.30 to 12.4), 
network estimate 12 23
11 more  
(9 fewer to 123 more)
⊕⊕⊕○, moderate,  
due to imprecision
Not calculated  
(non-statistically  
significant)
29.8
VKA  
(2 RCTs; 755 participants)
1.78 (0.95 to 3.34), 
network estimate 42 74
31 more  
(2 fewer to 88 more)
⊕○○○, very low, due to  
risk of bias, indirectness 
and imprecision
Not calculated  
(non-statistically  
significant)
24.4
ASA=aspirin; clopi=clopidogrel; NNH=number needed to harm; NNT=number needed to treat; RCT=randomised controlled trial; riva=rivaroxaban; SUCRA=surface under the cumulative ranking; 
SVGF=saphenous vein graft failure; tica=ticagrelor; VKA=vitamin K antagonist.
*Significant results are in bold.
†Data obtained directly from study sample (studies reporting outcome data), unless stated otherwise.
‡Larger SUCRA values indicate better interventions and higher hierarchy ranks are in bold.
§Saphenous vein graft failure (base case analysis), range of follow-up between one month and eight years.
¶Assumed risk (risk was assumed because of lack of direct evidence).
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We also downgraded the certainty of evidence to low 
or very low for most comparisons of clinical outcomes, 
including major bleeding, myocardial infarction, and 
mortality (fig 3, bottom panel, fig 5, and supplementary 
tables 8 and 9). However, comparisons with moderate 
certainty evidence should be interpreted with caution 
mainly because of inconsistency and publication bias. 
We could not thoroughly assess inconsistency because 
many of the comparisons consisted of a single study. 
Additionally, we could not assess publication bias 
for secondary outcomes because this network meta-
analysis was designed to exclude studies that did not 
evaluate our primary efficacy outcome (saphenous 
vein graft failure), regardless of reported secondary 
outcomes (supplementary tables 8 and 9).
Network assumptions
The distribution of potential effect modifiers was not 
balanced across comparisons; however, the evidence 
of intransitivity was inconclusive because of missing 
data in several comparisons (table 2). While we could 
not rule out the possibility of intransitivity (lack of 
similar characteristics across the studies and treatment 
comparisons), between-trial heterogeneity (τ2) was low 
in all included analyses compared with the expected 
value reported in the literature.49 Supplementary table 
9 shows direct and indirect estimates, and τ2. Loop 
specific approach (supplementary table 10) and design 
by treatment interaction models (supplementary table 
11) showed no evidence of incoherence between direct 
and indirect comparisons for all analyses.
Aspirin and
ticagrelor
Aspirin and ticagrelor
All cause mortality
Myocardial infarction
Aspirin and
rivaroxaban
Placebo
Placebo
Aspirin and clopidogrel
Aspirin and
clopidogrel
Aspirin
Aspirin
Rivaroxaban
Ticagrelor
Vit K A
Vit K A
1 trial
1 trial
1 trial
3 trials
4 trials
5 trials
2 trials
2 trials
2 trials
2 trials
2 trials
1 trial
1 trial
1 trial
1 trial
1 trial
Fig 4 | Network of treatment comparisons for secondary outcomes all cause mortality and myocardial infarction. 
Each node represents different active interventions or placebo. Size of nodes is proportional to number of studies 
comparing respective nodes. Increasing thickness of lines between nodes is proportional to number of randomly 
assigned patients contributing to direct comparisons. Vit K A=vitamin K antagonist
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Discussion
Principal findings
This systematic review included 20 parallel group 
randomised controlled trials of 4803 patients under-
going coronary artery bypass graft. The review com-
pared eight active antithrombotic interventions in a 
single framework to assess saphenous vein graft failure. 
The results of this network meta-analysis suggest that 
among active interventions and based on moderate 
certainty evidence, dual antiplatelet therapies with 
aspirin plus ticagrelor or aspirin plus clopidogrel were 
the most efficacious treatment regimens to prevent 
saphenous vein graft failure compared with aspirin 
monotherapy. However, the tradeoff was an increased 
risk of major bleeding, although the risk did not differ 
among the drug interventions.
Strengths and limitations of the study
The strength of our analysis is its robust design and 
transparency. We prespecified the research question 
and published a peer reviewed protocol23 for this 
systematic review of published randomised controlled 
trials of drug interventions to prevent saphenous vein 
graft failure after coronary artery bypass graft surgery. 
To increase the totality of evidence, we accounted for 
clustering effects of data expressed on a per graft basis, 
and made an inference at the patient level, which 
improved the applicability of the results in light of a 
newer P2Y12 inhibitor (ticagrelor) and direct factor Xa 
inhibitor (rivaroxaban). Our analysis adds new data 
on the use of dual antiplatelet therapy with aspirin 
plus ticagrelor and direct oral anticoagulation with 
rivaroxaban, thereby providing a better understanding 
of the role of these drug interventions to prevent 
saphenous vein graft failure after coronary artery 
bypass graft surgery.
The certainty of evidence for the saphenous vein 
graft failure endpoint was considered low or moderate 
for making a recommendation for most treatments 
compared with aspirin. Therefore, additional well 
designed research might change the findings.
For clinical (secondary) outcomes, the results of our 
network meta-analysis show no differences in effect 
estimates among multiple treatment comparisons; 
nonetheless, these were not our prespecified primary 
outcomes. Interestingly, the recently published and 
prematurely terminated trial that compared ticagrelor 
with aspirin after coronary artery bypass graft surgery 
showed no important differences in major adverse 
cardiovascular events or bleeding between the 
All cause mortality
Placebo
1.77
(0.52 to 5.99)
1.04
(0.23 to 4.72)
1.24
(0.01 to 114)
1.24
(0.13 to 11.5)
Aspirin
0.59
(0.19 to 1.87)
0.70
(0.01 to 54.3)
0.70
(0.11 to 4.50)
1.19
(0.01 to 107)
1.19
(0.13 to 10.6)
Aspirin +
Ticagrelor
Vitamin K
antagonists
1.00
(0.02 to 51.1)
Myocardial infarction
Placebo
0.49
(0.11 to 2.11)
0.45
(0.10 to 2.00)
0.33
(0.03 to 3.28)
0.47
(0.08 to 2.84)
0.34
(0.04 to 2.84)
0.25
(0.04 to 1.73)
0.34
(0.06 to 2.05)
0.92
(0.52 to 1.63)
0.68
(0.12 to 3.97)
0.96
(0.33 to 2.75)
0.70
(0.15 to 3.22)
0.52
(0.15 to 1.80)
0.71
(0.26 to 1.96)
Aspirin
0.74
(0.12 to 4.71)
1.04
(0.31 to 3.45)
0.76
(0.15 to 3.88)
0.57
(0.15 to 2.21)
0.77
(0.24 to 2.46)
Vitamin K
antagonists
1.40
(0.18 to 10.93)
1.03
(0.16 to 6.80)
0.77
(0.09 to 6.58)
1.04
(0.14 to 7.68)
Ticagrelor
0.74
(0.12 to 4.68)
0.55
(0.16 to 1.88)
0.74
(0.17 to 3.20)
Rivaroxaban
0.74
(0.10 to 5.27)
1.00
(0.18 to 5.74)
Aspirin +
Ticagrelor
1.35
(0.27 to 6.70)
Aspirin +
Rivaroxaban
Aspirin + 
Clopidogrel
Aspirin + 
Clopidogrel
Fig 5 | Network meta-analysis and certainty of evidence for secondary outcomes all cause mortality and myocardial infarction. Results are odds ratios 
(95% confidence intervals) from the network meta-analysis between the column defining intervention and the row defining intervention. Certainty of 
evidence is also given: green=moderate certainty evidence, yellow=low certainty evidence, red=very low certainty evidence
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monotherapies.50 These findings support the need for 
studies that evaluate dual antiplatelet therapy after 
coronary artery bypass graft surgery. Although our 
study might be underpowered to detect differences 
in clinical outcomes, further and larger randomised 
controlled trials that compare all the relevant 
antithrombotic strategies after coronary artery bypass 
graft surgery will be difficult to undertake with a mixed 
treatment comparison design. Therefore, our study is 
clinically meaningful and contributes up to date data 
to guide future directions in preventing saphenous 
vein graft failure after coronary artery bypass graft 
surgery.
In this study, we used a frequentist framework 
to perform the analysis as opposed to a Bayesian 
approach because the results of Bayesian analysis with 
non-informative priors are numerically equivalent 
to frequentist results. Although informative priors 
would make Bayesian methods more appealing than 
a frequentist framework, especially when dealing 
with small studies, such priors were not available. 
Therefore, the risk of using inaccurate informative 
priors can cause even more damage to the validity of 
the results.
Our study has several limitations. First, the quality 
of our analysis is limited by the inherent limitations 
of individual included trials. In particular, patient 
level data were not available, which precluded 
adjustment for any differences in clinical setting; 
for example, stable coronary artery disease versus 
acute coronary syndromes, elective versus urgent 
surgery, and on pump versus off pump coronary 
artery bypass graft surgery. In this study, more than 
80% of the patients underwent elective coronary 
artery bypass graft surgery; moreover, in the acute 
coronary syndrome setting, there is consensus among 
international guidelines that dual antiplatelet therapy 
is resumed soon after surgery and continued for one 
year (class  I).2  51 52 Also, we were unable to perform 
competing risk analysis. If we had reported measures 
of effects that reflect time to event (that is, hazard 
ratio), the results would have been more informative. 
However, the studies that were eligible for this review 
did not report these measures.
Second, although we presented full details about the 
risk of bias of all included trials (supplementary table 
7), many trials did not report adequate information 
about allocation sequence concealment, proportions of 
and reasons for missing outcome data, and how trials 
handled missing data. This lack of information could 
have led to inaccurate interpretation of the certainty of 
evidence. Third, different trials used different outcome 
definitions and also various imaging follow-up protocols, 
which could have threatened the internal validity of our 
network meta-analysis. Although our sensitivity analysis 
showed no substantial differences in effect estimates 
between per graft and per patient analyses for most 
comparisons, the credibility of this data driven approach 
remains unclear. Fourth, we combined studies using 
different doses of the same drug intervention in the same 
node, and assumed that there would be no systematic 
differences in treatment effects across doses. Fifth, the 
trials in which most of patients underwent off pump 
coronary artery bypass graft surgery,16 35 36 the dose of 
aspirin (monotherapy or dual antiplatelet therapy) was 
81-100 mg daily. However, we were unable to compare 
and confirm the potential benefit of higher doses (such 
as 160-325 mg) of aspirin in patients undergoing 
off pump procedures because of a lack of off pump 
trials using these doses of aspirin. Nevertheless, when 
combined with a P2Y12 inhibitor, the recommended 
dose of aspirin is less than 100 mg daily.
Sixth, our network meta-analysis included trials 
published over a 39 year period, which might not reflect 
the current clinical practice; for example, patient 
characteristics, surgical techniques (eg, off pump 
coronary artery bypass graft), drug regimens (early 
trials were more likely to compare against placebo and 
later trials were more likely to be active comparator 
trials), and secondary prevention strategies18 (sta-
tins, angiotensin converting enzyme inhibitors, or 
angiotensin receptor blockers and β blockers). There-
fore, changes in adjunct medical treatment over time 
could potentially affect treatment estimates. Post hoc 
meta-regression analysis did not show evidence of 
an association between treatment effect and year of 
publication for some treatments. However, it was not 
possible to estimate the effect of publication year for 
all treatments owing to multicollinearity and missing 
linkage (supplementary table 12). We performed a 
sensitivity analysis stratified by publications before 
and after the year 2000 (supplementary figure 3), and 
the findings did not change the treatment effect when 
the results were split by more recent trials. Finally, 
legacy or post trial persistent treatment effect was 
explored. While the sensitivity analysis did not change 
the effect estimates, this was based on a single study 
that reported saphenous vein graft failure at one37and 
eight24 years.
Comparison with other studies
Aspirin monotherapy is currently recommended 
for patients with stable coronary artery disease 
after coronary artery bypass graft surgery to reduce 
saphenous vein graft failure.18 In patients who present 
with acute coronary syndromes, dual antiplatelet 
therapy is recommended to be resumed soon after 
coronary artery bypass graft surgery.2 51 52 However, 
there is a lack of evidence that dual antiplatelet therapy 
is associated with a decrease in thromboembolic 
complications or mortality in patients with stable 
coronary artery disease undergoing coronary artery 
bypass graft surgery.53 Few observational and 
randomised data suggest that additional drug 
intervention with dual antiplatelet therapy reduces 
the risk of saphenous vein graft failure. This effect 
appears to be more pronounced in patients undergoing 
off pump coronary artery bypass graft surgery than 
on pump coronary artery bypass graft surgery, or for 
arterial graft recipients.54 55
The 2016 American guidelines51 recommend that 
in patients with stable coronary artery disease, aspirin 
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81 mg (75-100 mg) plus clopidogrel (started early after 
surgery) for 12 months after coronary artery bypass 
graft might be reasonable to improve saphenous vein 
graft patency (class IIb, level of evidence B). Conversely, 
the 2017 European guidelines state that there is 
insufficient evidence to generally recommend dual 
antiplatelet therapy to reduce saphenous vein graft 
failure.53 To mitigate the relative hypercoagulable state 
that off pump patients experience, the 2015 American 
Heart Association scientific statement18 recommends 
the combination of aspirin and clopidogrel after off 
pump coronary artery bypass graft surgery (class I, 
level of evidence A). However, the European guidelines 
state that there is weak evidence to support dual 
antiplatelet therapy in this subset of patients,53 and 
the American guidelines51 do not comment on this.
The clinical benefits of adding a P2Y12 inhibitor 
to aspirin originate from the Clopidogrel in Unstable 
Angina to Prevent Recurrent Events (CURE) trial. 
Participants with non-ST elevation acute coronary 
syndromes who were allocated to receive aspirin 
plus clopidogrel experienced a major reduction in 
the composite outcome of death from cardiovascular 
causes, non-fatal myocardial infarction, or stroke, and 
a range of related ischaemic events.56 However, there 
was a tradeoff of increased risk of bleeding, and most 
of the major bleeding events were gastrointestinal and 
arterial access site bleeds.56 In our analysis, although 
the occurrence of major bleeding with aspirin plus 
ticagrelor was not statistically significant compared 
with aspirin alone, the network estimates showed an 
odds ratio of 1.93, and wide 95% confidence intervals 
(0.30 to 12.4) compared with aspirin plus clopidogrel 
(0.85, 0.30 to 2.37). The lack of different doses of 
clopidogrel precludes further analysis. Notably, the 
combination of aspirin plus rivaroxaban 2.5 mg 
twice daily or rivaroxaban 5 mg twice daily alone did 
not reduce saphenous vein graft failure compared 
with aspirin alone in the COMPASS (Cardiovascular 
OutcoMes for People Using Anticoagulation StrategieS) 
coronary artery bypass graft trial.17 However, the 
combination of aspirin plus rivaroxaban 2.5 mg twice 
daily was associated with similar reductions in major 
adverse cardiovascular events, and this was consistent 
with the findings of the main COMPASS trial.57 
Therefore, because major bleeding has been associated 
with increased morbidity and mortality,58 59 the risk 
of bleeding should be carefully balanced against the 
benefits when planning long term (>12 months) dual 
antiplatelet therapy in patients undergoing coronary 
artery bypass graft surgery.
Unanswered questions and future research
We did not have enough power to detect significance for 
clinical outcomes because we restricted the inclusion 
to trials that reported saphenous vein graft failure (our 
primary outcome), hence reducing statistical power 
in this regard. However, the eligibility criteria were 
purposefully stringent to reduce heterogeneity and risk 
of bias. Saphenous vein graft failure is not a clinical 
outcome in itself; it is considered a surrogate endpoint 
of myocardial infarction or repeat revascularisation. 
However, not all saphenous vein grafts are the same 
because of individual graft quality or technical (that 
is, anastomoses) matters. Additionally, the grafts 
depend on which are the target vessels, the severity of 
stenosis and ischemia,60 and the territory and amount 
of myocardium being supplied by a given graft. Hence, 
saphenous vein graft failure will occur because 
of physiological or functional causes rather than 
saphenous vein graft driven thrombotic mechanisms, 
yet without apparent clinical consequence.60 61 Lopes 
and colleagues61 showed that saphenous vein graft 
failure was associated with an increased risk for the 
composite of death, myocardial infarction, or repeat 
revascularisation at four years after the angiogram. 
However, this association was mainly because of repeat 
revascularisation; there were no differences in terms 
of death or the composite of death and myocardial 
infarction among individuals with and without 
saphenous vein graft failure.61 These findings highlight 
the confounded association between saphenous 
vein graft failure and major adverse cardiovascular 
events. Therefore, when saphenous vein graft failure is 
accompanied by clinical symptoms,61 for example new 
onset angina and progressive symptoms of angina, 
or hospital admission for acute coronary syndromes 
leading to revascularisation, this could be more 
relevant for prognosis and patient preferences and 
values.
Not all the included trials reported the actual data 
on duration of treatment. Therefore, patients might 
have received different durations of antithrombotic 
treatments, which resulted in patient level covariate 
effects. Post hoc meta-regression analysis did not 
show evidence of an association between duration of 
treatment (originally prespecified by the trial authors, 
not actual duration) and treatment effect for some 
drug interventions; however, it was not possible 
to estimate the effect of treatment duration for all 
treatments because of multicollinearity and missing 
linkage (supplementary table 13). Moreover, this meta-
regression probably had low power to detect such an 
association, and its credibility is questionable owing to 
the lack of patient level data; therefore, it is subject to 
ecological bias.
Further research is needed to improve strategies to 
optimise saphenous vein graft patency after coronary 
artery bypass graft surgery. We need studies of adequate 
duration and sample size that report saphenous vein 
graft failure at different time points to determine the 
potential legacy effect of dual antiplatelet therapy 
during the first year after coronary artery bypass graft 
surgery. Additionally, these studies should report long 
term (that is, five or 10 years) incidence of saphenous 
vein graft failure, and patient important outcomes 
(mortality, ischaemic, or bleeding events).
Conclusion and policy implications
The results of this network meta-analysis suggest an 
important absolute benefit of adding ticagrelor or 
clopidogrel to aspirin to prevent saphenous vein graft 
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failure after coronary artery bypass graft surgery. Dual 
antiplatelet therapy after surgery should be tailored to 
the patient by balancing the safety and efficacy profile 
of the drug intervention against important patient 
outcomes. Future guideline updates are needed to 
optimise antithrombotic management of patients 
undergoing coronary artery bypass graft surgery. 
Meanwhile, dual antiplatelet therapy with aspirin 
plus ticagrelor or aspirin plus clopidogrel could be 
considered for most patients after surgery.
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